Genprex Inc
Change company Symbol lookup
Select an option...
GNPX Genprex Inc
OKTA Okta Inc
APD Air Products and Chemicals Inc
DUK Duke Energy Corp
NKE Nike Inc
AAPL Apple Inc
VXRT Vaxart Inc
VIGI Vanguard International Dividend Appreciation Index Fund ETF Shares
VIG Vanguard Dividend Appreciation Index Fund ETF Shares
VIAC ViacomCBS Inc
Go

Health Care : Biotechnology |
Company profile

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).

Premarket

Last Trade
Delayed
$3.60
0.02 (0.56%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$3.58
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
1,290

10-day average volume:
783,078
1,290

Latest Earnings (Q2 ending 06/2020)

Q2
-$0.12
Q2 Consensus estimate
-$0.13

Latest Earnings Estimate Range

Highest
estimate
-$0.07
Mean
estimate
-$0.13
Lowest
estimate
-$0.19

Quarterly Consensus Estimates and Ranges

GNPX's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.